Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday
Thanks largely to news of a crucial legal settlement, GSK ( GSK 5.84%) was one of the better-performing big pharma stocks on Wednesday. Relieved investors showed their appreciation by collectively ...
GSK: The Worst Is Finally Over (Rating Upgrade)
GSK's share price rose 6% after settling 93% of Zantac cases, impacting Q3 earnings; forward non-GAAP P/E remains reasonable ...
FiercePharma3d
GSK will pony up $2.2B to resolve 80K Zantac cases
The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.
GSK Bought More Shares of Biotech Wave Life Sciences
GSK paid $22.4 million on Sept. 27 for 2.8 million more shares of Wave Life Sciences for $8 each. GSK now owns 16.8 million ...
GSK’s problem is it has more than one source of pain
Zantac settlement should ease investors’ nervousness but long-standing concerns about drugmaker’s pipeline remain ...
FTSE 100 Live 10 October: GSK shares rise on $2.2bn Zantac settlement, property firm gets £1.1bn bid
GSK’s $2.2 billion Zantac settlement today put its shares top of the FTSE 100, albeit still well short of their level before ...
UK stocks slip as some companies trade ex-dividend; GSK shines
The UK's main stock indexes slipped on Thursday as some of the companies traded without the entitlement of their dividend pay ...